Core Insights - Two brain-computer interface (BCI) companies in Shanghai have made significant advancements in their research, with one company, JieTi Medical, having its "implantable wireless brain-computer interface system" enter the special review process of the National Medical Products Administration, marking it as the first invasive BCI product to enter the "green channel" in China [1] - The other company, Boda Medical, is developing an "ultrasound brain-computer interface" that aims to achieve high spatiotemporal resolution for comprehensive brain function analysis [1] Company Developments - JieTi Medical has invented ultra-flexible electrodes that are 1/100th the diameter of a human hair, significantly reducing the risk of tissue damage and immune response when implanted in the brain [1] - JieTi Medical is collaborating with Huashan Hospital for prospective clinical trials, which have shown initial success in restoring some self-care abilities in patients [1] - Boda Medical's founder introduced a new ultrasound technology with a frame rate of 10,000 frames per second, which surpasses traditional imaging techniques like fMRI and PET in sensitivity [2] - Boda Medical has developed an ultrasound brain blood flow imaging system that is currently being used in clinical settings, showing promising results [2] Industry Trends - The brain-computer interface sector is identified as a key future industry in China, gaining global attention since the establishment of Neuralink by Elon Musk in 2016 [1] - The advancements in BCI technology are expected to facilitate broader applications in areas such as motor and language function replacement, treatment of neurological diseases, and sensory restoration [2] - The 2025 "Innovation in Shanghai" international entrepreneurship competition aims to attract investment for the development of hard-tech startups, including Boda Medical's ultrasound BCI technology [4]